ISELIN, N.J., Aug. 29 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) today announced that effective October 31, 2008 it will cease operations in Rehovot, Israel, and manage those activities currently based in Rehovot out of the Company's US headquarters in Iselin, New Jersey.
The research programs in Israel are the CB2 receptor selective library of compounds, including preclinical development of PRS-639,058 for neuropathic pain. Additionally the Company has almost completed a Phase 2a trial with its proprietary 3% diclofenac NanoEmulsion cream for use as a topical treatment for osteoarthritis pain.
The Company's strategy is to seek a partner who will take the lead in both operating and funding the research programs in Israel. To facilitate these efforts, the Company engaged and has been working with a boutique life science investment bank. Interested parties can contact Ashish Sanghrajka at BIO-IB at 212-332-4388 or Colin Neill, President & CFO, Pharmos Corporation at 732-452- 9556.
Additionally, the Rehovot senior management team of Iris Alroy, PhD and Arnon Aharon MD will remain available to support ongoing business development and existing collaborations as consultants.
About Pharmos Corporation
Pharmos discovers and develops novel therapeutics to treat a range of
indications including specific diseases of the nervous system such as
disorders of the brain-gut axis (GI/IBS), pain/inflammation, and autoimmune
disorders. The Company's lead product in development, dextofisopam, is
undergoing Phase 2b testing in IBS patients. Dextofisopam has completed a
Phase 2a IBS study in which it demonstrated a statistically significant
effect compared to placebo on the primary efficacy endpoint of adequ
|SOURCE Pharmos Corporation|
Copyright©2008 PR Newswire.
All rights reserved